近距放疗联合间歇性内分泌治疗在前列腺癌治疗中的应用

李青; 李明川; 姜永光; 王永兴; 刘俊敏

近距放疗联合间歇性内分泌治疗在前列腺癌治疗中的应用

- 首都医科大学附属北京安贞医院泌尿外科(北京, 100029)

详细信息

通讯作者: 李青,E-mail:leeching@holine.com

中图分类号: R737.25

收稿日期: 2011-04-02

The joint application of brachytheraphy and intermittent hormonal therapy in treating prostate cancer

- Department of Urology, Beijing Anzhen Hospital, Beijing, 100029, China

More Information

Corresponding author: LI Qing, E-mail: leeching@holine.com

Received Date: 02 April 2011

摘要

摘要: 目的：分析比较¹²⁵I粒子植入近距放疗联合间歇性内分泌治疗在前列腺癌治疗中的效果。方法：回顾2001年1月~2011年2月期间未接受根治性前列腺切除而接受治疗满5年的147例前列腺癌患者，按治疗方式分为三组；A组43例单纯采用间歇性内分泌治疗；B组31例单纯采用近距离¹²⁵I粒子植入；C组73例施行近距离¹²⁵I粒子植入+间歇性内分泌治疗。比较三组患者的临床症状、PSA变化情况、局部进展率、无事件生存率。结果：147例患者，A组5年生存率为88.37%，无效率13.95%，无事件生存率16.28%；B组生存率为90.32%，无效率22.58%，无事件生存率32.26%；C组生存率为90.41%，无效率6.85%，无事件生存率34.25%。结论：近距离¹²⁵I粒子植入+间歇性内分泌联合治疗作为前列腺癌的综合治疗手段，可以提高无事件生存率、增加治疗有效率、缩短内分泌治疗时间。
- 前列腺癌 /
- 近距放疗 /
- 内分泌治疗
Abstract: Objective: Analysis and comparison of ¹²⁵I seed implantation and intermittent endocrine therapy for prostate cancer.Method: Between January 2001 and February 2011,The clinic records of 147 men with prostate carcinoma who had not received radical prostatectomy,were divided into 3 groups according to the treatment:Group A consists of 43 cases that received simple use of intermittent endocrine therapy; Group B consists of 31 patients who received ¹²⁵I brachytherapy; Group C contains 73 patients who underwent ¹²⁵I brachytherapy plus intermittent endocrine therapy.To compare with the three groups include clinical symptoms,PSA changes,local progression rate,and event-free survival.Result: 147 cases were followed up ≥ 5 years.Group A 5-year survival rate was 88.37%,13.95% inefficiency,event-free survival rate was 16.28%; Group B survival rate was 90.32%,22.58% inefficiency,event-free survival rate was 32.26%; Group C survival rate was 90.41%,inefficiency of 6.85%,event-free survival rate of 34.25%.Conclusion: The close-¹²⁵I seed implantation and intermittent hormonal therapy as a comprehensive treatment of prostate cancer can improve event-free survival,increase treatment efficiency,shorten time to endocrine therapy.
- prostatic neoplasms /
- brachytherapy /
- endocrine therapy

HTML全文

参考文献(11)

[1]	SYLVESTER J E,BLASKO J C,GRIMM P D,et al.Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer:the Seattle experience[J].Int J Radiat Oncol Biol Phys,2003,57:944-952.
[2]	AUS G,HUGOSSON J,NORLÉN L.Need for hospital care and palliative treatment for postate cancer treated with noncurative intent[J].J Urol,1995:154:466-469.
[3]	AUS G,HUGOSSON J,NORLÉN L.Long-term survival and mortality in prostate cancer treated with noncurative intent[J].J Urol,1995:154:460-465.
[4]	ROACH M 3rd,HANKS G,THAMES H JR,et al.Defi ning biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer:recommendations of the RTOG-ASTRO Phoenix Consensus Conference[J].Int J Radiat Oncol Biol Phys,2006,65:965-974.
[5]	HILLARIS B S,WHITMORE J R W F,BATATA M A,et al.Cancer of the prostate[M]//HILLARIS B S,editor.Handbook of interstitial brachytherapy.New York,NY:Memorial Sloan-Kettering Cancer Center,1975:219-233.
[6]	NADERI N,BEEK J V. Transperineal Permanent Brachytherapy of Localised Prostate Cancer[J].European Urology Supplements, 2008, 12:732-741.
[7]	GREEN N,BODNER H,BROTH E,et al.Improved control of bulky prostate carcinoma with sequential estrogen and radiation therapy[J].Int J Radiat Oneol Biol Phys,1984,10:971-976.
[8]	CROOK J, LUDGATE C, MALONE S, et al. Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer[J]. Int J Radiat Oncol Biol Phys, 2009, 73:327-333.
[9]	BLASKO J C,GRIMM P D,SYLVESTER J E,et al.Palladium-103 brachytherapy for prostate carcinoma[J].Int J Radiation Oncology Bio Phys,2000,46:839-850.
[10]	MERRICK G S,BUTLER W M,GALBREATH R W,et al.Five-year biochemical outcome following permanent interstitial brachytherapy for clinical Tl-T3 prostate cancer[J].Int J Radiat Oncol Biol Phys,2001,51:41-48.
[11]	ZELEFSKY M J,WALLNER K E,LING C C,et al.Comparison of the 5-Year Outcome and Morbidity of Three-Dimensional Conformal Radiotherapy Versus Transperineal Permanent Iodine-125 Implantation for Early-Stage Prostatic Cancer[J].J Clin Oncol,1999,17,2:517-520.